Bifeprunox - Atypical Antipsychotic Drug
Key Data:
Drug (brand / generic)
Bifeprunox mesilate
Company / licensee
Solvay Pharmaceuticals / Lundbeck / Wyeth
Therapy class
Antipsychotic
Product description
Partial dopamine D2 agonist
Current indication
Treatment of schizophrenia
Market sector
CNS
Development status
Phase III Europe; rejected by FDA in US
